Research Activity
ReSync Bio, Sapio Sciences adopt Nvidia BioNeMo to supercharge AI drug discovery
Drug Discovery, Aortic Valve Insufficiency, Sapio, Sapio Sciences, Bio, NVIDIA ‘s, BioNeMo, microservices
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III
eneboparatide, hypoparathyroidism, Phase III trial, Calypso study, Amolyt Pharma acquisition
Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic
Latigo Biotherapeutics, non-opioid pain drugs, Nav1.8 inhibitors, Series B funding, clinical trials, acute pain, chronic pain
Future-proofing gene therapy assays: Validation strategies for long-term success
Long-term, Validation, Biological Assay, Develop
MeiraGTx and Hologen AI Form $430M Collaboration to Advance Parkinson’s Gene Therapy
gene therapy, Parkinson’s disease, artificial intelligence, clinical trials, biotechnology partnership
Insilico secures $110M in new funding for AI-designed pipeline
Clinical Trials, Aortic Valve Insufficiency
Gilead hops straight to Phase III with once-yearly HIV PrEP shot
PREP gene, formulations, once-yearly, Trial Phase
Mixed pivotal data for Pfizer, Arvinas’ protein degrader in breast cancer
Pfizer, Vepdegestrant, Clinical Trials, ESR1 gene, Statistical Significance, Improvement, Progression-Free Survival, Market
Novo Nordisk’s CagriSema Weight Loss Drug Trial Results Disappoint Investors
CagriSema, weight loss, clinical trial, Novo Nordisk, stock price drop, obesity treatment